Showing results (111-120 of 251) with videos related to

Sort By:
Pageof 26
Plos One|June 17, 2009
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85AKathryn T Whelan, Ansar A Pathan, Clare R Sander, et al.
Tuberculosis (Edinburgh, Scotland)|June 4, 2013
Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb)Leanne Marsay, Magali Matsumiya, Rachel Tanner, et al.
European Journal of Immunology|June 6, 2013
Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell functionOne B Dintwe, Cheryl L Day, Erica Smit, et al.
F1000Research|June 16, 2018
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosyHelen A Fletcher, Mitali Chatterjee, Andrea Cooper, et al.
Health Promotion Practice|February 18, 2004
Setting objectives for community and systems change: an application of concept mapping for planning a statewide health improvement initiativeWilliam M K Trochim, Bobby Milstein, Betty J Wood, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2010
Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of ageSarah Burl, Uche J Adetifa, Momodou Cox, et al.
Plos One|September 3, 2011
Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AKristin L Griffiths, Ansar A Pathan, Angela M Minassian, et al.
Vaccine|December 26, 2012
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryJoel Meyer, Stephanie A Harris, Iman Satti, et al.
Plos One|July 12, 2013
Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85AMagali Matsumiya, Elena Stylianou, Kristin Griffiths, et al.
The Journal of Infection|June 19, 2024
Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular routeRégine Audran, Olfa Karoui, Laura Donnet, et al.
Pageof 26